S&P 500   3,110.40 (+0.44%)
DOW   27,898.54 (+0.42%)
QQQ   202.50 (+0.53%)
CGC   15.66 (-1.14%)
BABA   184.84 (+1.11%)
GE   11.44 (+1.33%)
T   39.11 (+0.41%)
F   8.94 (+1.71%)
ACB   3.08 (-6.38%)
DIS   146.30 (-0.58%)
S&P 500   3,110.40 (+0.44%)
DOW   27,898.54 (+0.42%)
QQQ   202.50 (+0.53%)
CGC   15.66 (-1.14%)
BABA   184.84 (+1.11%)
GE   11.44 (+1.33%)
T   39.11 (+0.41%)
F   8.94 (+1.71%)
ACB   3.08 (-6.38%)
DIS   146.30 (-0.58%)
S&P 500   3,110.40 (+0.44%)
DOW   27,898.54 (+0.42%)
QQQ   202.50 (+0.53%)
CGC   15.66 (-1.14%)
BABA   184.84 (+1.11%)
GE   11.44 (+1.33%)
T   39.11 (+0.41%)
F   8.94 (+1.71%)
ACB   3.08 (-6.38%)
DIS   146.30 (-0.58%)
S&P 500   3,110.40 (+0.44%)
DOW   27,898.54 (+0.42%)
QQQ   202.50 (+0.53%)
CGC   15.66 (-1.14%)
BABA   184.84 (+1.11%)
GE   11.44 (+1.33%)
T   39.11 (+0.41%)
F   8.94 (+1.71%)
ACB   3.08 (-6.38%)
DIS   146.30 (-0.58%)
Log in

Agios Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:AGIO)

$35.81
+1.60 (+4.68 %)
(As of 11/15/2019 11:00 AM ET)
Today's Range
$34.75
Now: $35.81
$35.93
50-Day Range
$29.46
MA: $33.31
$35.89
52-Week Range
$28.36
Now: $35.81
$70.70
Volume7,872 shs
Average Volume1.21 million shs
Market Capitalization$2.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.22
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AGIO
CUSIPN/A
Phone617-649-8600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$94.39 million
Book Value$7.61 per share

Profitability

Net Income$-346,020,000.00
Net Margins-356.42%

Miscellaneous

Employees482
Market Cap$2.11 billion
Next Earnings Date2/13/2020 (Estimated)
OptionableOptionable

Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.


Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals Inc (NASDAQ:AGIO) released its earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, beating analysts' consensus estimates of ($1.85) by $0.04. The biopharmaceutical company had revenue of $26.02 million for the quarter, compared to analysts' expectations of $33.13 million. Agios Pharmaceuticals had a negative net margin of 356.42% and a negative return on equity of 70.07%. Agios Pharmaceuticals's revenue for the quarter was up 71.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.63) EPS. View Agios Pharmaceuticals' Earnings History.

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Agios Pharmaceuticals.

What price target have analysts set for AGIO?

11 brokers have issued 1 year target prices for Agios Pharmaceuticals' shares. Their forecasts range from $45.00 to $80.00. On average, they expect Agios Pharmaceuticals' stock price to reach $64.88 in the next twelve months. This suggests a possible upside of 81.2% from the stock's current price. View Analyst Price Targets for Agios Pharmaceuticals.

What is the consensus analysts' recommendation for Agios Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agios Pharmaceuticals.

Has Agios Pharmaceuticals been receiving favorable news coverage?

Headlines about AGIO stock have been trending somewhat negative this week, InfoTrie reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Agios Pharmaceuticals earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Agios Pharmaceuticals.

Are investors shorting Agios Pharmaceuticals?

Agios Pharmaceuticals saw a decrease in short interest in the month of October. As of October 15th, there was short interest totalling 10,910,000 shares, a decrease of 5.1% from the September 15th total of 11,500,000 shares. Based on an average trading volume of 594,900 shares, the short-interest ratio is currently 18.3 days. Approximately 18.8% of the shares of the stock are short sold. View Agios Pharmaceuticals' Current Options Chain.

Who are some of Agios Pharmaceuticals' key competitors?

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Celgene (CELG), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), Alibaba Group (BABA), bluebird bio (BLUE), Tesla (TSLA), Allergan (AGN), Ionis Pharmaceuticals (IONS) and Micron Technology (MU).

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the folowing people:
  • Jacqualyn A. Fouse, Chief Executive Officer & Director
  • Andrew J. Hirsch, CFO & Head-Corporate Development
  • Scott Biller, Chief Scientific Officer
  • Chris Bowden, Chief Medical Officer
  • Clive Patience, Senior Vice President-Technical Operations

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (2.20%), Rhenman & Partners Asset Management AB (0.42%), Handelsbanken Fonder AB (0.27%), Alps Advisors Inc. (0.20%), ZWJ Investment Counsel Inc. (0.20%) and California Public Employees Retirement System (0.15%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, David Scadden, John Maraganore, Kaye I Foster-Cheek, Lewis Clayton Jr Cantley, Scott Biller and Steven L Hoerter. View Institutional Ownership Trends for Agios Pharmaceuticals.

Which institutional investors are selling Agios Pharmaceuticals stock?

AGIO stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Handelsbanken Fonder AB and Alps Advisors Inc.. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Christopher Bowden, Scott Biller and Steven L Hoerter. View Insider Buying and Selling for Agios Pharmaceuticals.

Which institutional investors are buying Agios Pharmaceuticals stock?

AGIO stock was acquired by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Rhenman & Partners Asset Management AB, ZWJ Investment Counsel Inc., California Public Employees Retirement System, Wealthstreet Investment Advisors LLC, Rhumbline Advisers, First Mercantile Trust Co. and Steward Partners Investment Advisory LLC. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene and David Scadden. View Insider Buying and Selling for Agios Pharmaceuticals.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $35.81.

How big of a company is Agios Pharmaceuticals?

Agios Pharmaceuticals has a market capitalization of $2.11 billion and generates $94.39 million in revenue each year. The biopharmaceutical company earns $-346,020,000.00 in net income (profit) each year or ($6.03) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe.View Additional Information About Agios Pharmaceuticals.

What is Agios Pharmaceuticals' official website?

The official website for Agios Pharmaceuticals is http://www.agios.com/.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]


MarketBeat Community Rating for Agios Pharmaceuticals (NASDAQ AGIO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  397 (Vote Outperform)
Underperform Votes:  344 (Vote Underperform)
Total Votes:  741
MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe AGIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Featured Article: Intrinsic Value

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel